Get the Stockscreener App
1.96
11.36%
0.20
After Hours:
1.98
0.02
+1.02%
Gain Therapeutics Inc stock is traded at $1.96, with a volume of 1.13M.
It is up +11.36% in the last 24 hours and up +10.73% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$1.76
Open:
$1.8
24h Volume:
1.13M
Relative Volume:
1.75
Market Cap:
$70.46M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.7818
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-1.01%
1M Performance:
+10.73%
6M Performance:
-4.39%
1Y Performance:
-21.60%
1-Day Range:
$1.775
$1.98
1-Week Range:
$1.74
$2.08
52-Week Range:
$1.41
$2.81
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.96 | 63.27M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Using R and stats models for Gain Therapeutics Inc. forecastingJuly 2025 Institutional & Verified Swing Trading Watchlist - newser.com
Can Gain Therapeutics Inc. stock deliver sustainable ROEMarket Sentiment Review & Entry Point Confirmation Signals - newser.com
Is Gain Therapeutics Inc. stock a buy before product launches2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
Will Gain Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Levels & Smart Allocation Stock Tips - newser.com
Sentiment analysis tools applied to Gain Therapeutics Inc.Quarterly Trade Review & Weekly Market Pulse Updates - newser.com
Advanced analytics toolkit walkthrough for Gain Therapeutics Inc.Risk Management & Fast Moving Market Watchlists - newser.com
Is Gain Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Closing Moves & High Accuracy Trade Alerts - newser.com
Gain Therapeutics Inc. stock trend outlook and recovery pathWeekly Profit Summary & Fast Exit and Entry Strategy Plans - newser.com
How risky is Gain Therapeutics Inc. stock nowMarket Trend Review & Stepwise Trade Signal Implementation - newser.com
Using Python tools to backtest Gain Therapeutics Inc. strategiesMarket Movement Recap & Reliable Breakout Forecasts - newser.com
Is Gain Therapeutics Inc. stock entering bullish territoryJuly 2025 Update & Fast Entry High Yield Tips - newser.com
Is Gain Therapeutics Inc. stock ready for a breakoutJuly 2025 WrapUp & Daily Volume Surge Signals - newser.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 200.7% in October - MarketBeat
Gain Therapeutics, Inc. (GANX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Can machine learning forecast Gain Therapeutics Inc. recoveryJuly 2025 Spike Watch & Growth Focused Investment Plans - newser.com
Gain Therapeutics Advances Parkinson’s Treatment with GT-02287 Study - MSN
Gain Therapeutics to Present at Neuroscience 2025 - The Manila Times
Gain Therapeutics (NASDAQ: GANX) to present GT-02287 poster at Society for Neuroscience - Stock Titan
What technical charts say about Gain Therapeutics Inc. stock2025 Historical Comparison & Fast Gain Stock Trading Tips - newser.com
Is Gain Therapeutics Inc. stock undervalued vs historical averagesWeekly Market Outlook & Accurate Technical Buy Alerts - newser.com
What drives Gain Therapeutics Inc stock priceTechnical Breakout Signals & Free Real-Time Stock Market Data - earlytimes.in
How Gain Therapeutics Inc. stock reacts to inflationary pressuresProfit Target & Weekly Return Optimization Alerts - Fundação Cultural do Pará
What risks investors should watch in Gain Therapeutics Inc. stockJuly 2025 Retail & Stock Portfolio Risk Management - Fundação Cultural do Pará
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):